



1P-655-C025

## Monoclonal Antibody to CD28 (rat) Phycoerythrin (PE) conjugated (0.025 mg)

<b>Clone:</b>	JJ319
<b>Isotype:</b>	Mouse IgG1
<b>Specificity:</b>	The mouse monoclonal antibody JJ319 reacts with CD28, a disulfide-linked homodimeric type I glycoprotein (monomer of Mw 44 kDa) which is a critical costimulatory receptor of T cells.
<b>Regulatory Status:</b>	RUO
<b>Immunogen:</b>	Mouse A20J B lymphoma cells transfected with rat CD28
<b>Species Reactivity:</b>	Rat
<b>Preparation:</b>	The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography.
<b>Concentration:</b>	0.5 mg/ml
<b>Storage Buffer:</b>	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
<b>Storage / Stability:</b>	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
<b>Usage:</b>	The reagent is designed for Flow Cytometry analysis.
<b>Expiration:</b>	See vial label
<b>Lot Number:</b>	See vial label
<b>Background:</b>	CD28 is the critical T cell costimulatory receptor which provides to the cell the important second activation signal by binding CD80 and CD86 that are expressed by antigen presenting cells. Besides its costimulation role CD28 functions in preventing T cells from anergic hyporesponsive state or from undergoing premature apoptotic cell death. Its analog CTLA-4, expressed on the surface of activated T cells, has higher affinity to CD80 and CD86 than CD28 and downregulates T cell activity.

**For laboratory research only, not for drug, diagnostic or other use.**

**Antibodies****References:**

- \*Tacke M, Hanke G, Hanke T, Hünig T: CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. *Eur J Immunol.* 1997 Jan;27(1):239-47.
- \*Robinson LE, Clandinin MT, Field CJ: R3230AC rat mammary tumor and dietary long-chain (n-3) fatty acids change immune cell composition and function during mitogen activation. *J Nutr.* 2001 Jul;131(7):2021-7.
- \*Haspot F, Villemain F, Laflamme G, Coulon F, Olive D, Tiollier J, Soullillou JP, Vanhove B: Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses. *Blood.* 2002 Mar 15;99(6):2228-34.
- \*Dengler TJ, Szabo G, Sido B, Nottmeyer W, Zimmerman R, Vahl CF, Hünig T, Meuer SC: Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation. *Transplantation.* 1999 Feb 15;67(3):392-8.
- \*Lühder F, Huang Y, Dennehy KM, Guntermann C, Müller I, Winkler E, Kerkau T, Ikemizu S, Davis SJ, Hanke T, Hünig T: Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. *J Exp Med.* 2003 Apr 21;197(8):955-66.
- \*Laskowski IA, Pratschke J, Wilhelm MJ, Dong VM, Beato F, Taal M, Gasser M, Hancock WW, Sayegh MH, Tilney NL: Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. *J Am Soc Nephrol.* 2002 Feb;13(2):519-27.
- \*van den Brandt J, Wang D, Reichardt HM: Resistance of single-positive thymocytes to glucocorticoid-induced apoptosis is mediated by CD28 signaling. *Mol Endocrinol.* 2004 Mar;18(3):687-95.
- \*Kerstan A, Armbruster N, Leverkus M, Hünig T: Cyclosporin A abolishes CD28-mediated resistance to CD95-induced apoptosis via superinduction of caspase-3. *J Immunol.* 2006 Dec 1;177(11):7689-97.
- \*Guillonnet C, Séveno C, Dugast AS, Li XL, Renaudin K, Haspot F, Usal C, Veziers J, Anegon I, Vanhove B: Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. *J Immunol.* 2007 Dec 15;179(12):8164-71.
- \*And many other.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at [www.exbio.cz](http://www.exbio.cz).

**For laboratory research only, not for drug, diagnostic or other use.**

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic  
Tel: +420 261 090 666 | Fax: +420 261 090 660 | [orders@exbio.cz](mailto:orders@exbio.cz) | [www.exbio.cz](http://www.exbio.cz)